Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

@article{Rasmussen2016ShockingHO,
  title={Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?},
  author={T. Rasmussen and S. Lewin},
  journal={Current Opinion in HIV and AIDS},
  year={2016},
  volume={11},
  pages={394–401}
}
  • T. Rasmussen, S. Lewin
  • Published 2016
  • Medicine
  • Current Opinion in HIV and AIDS
  • Purpose of reviewTo provide an overview of the initial experiences with the use of latency-reversing agents (LRAs) in clinical trials in HIV and to discuss and contrast results arising from these studies. Recent findingsAlthough the clinical administration of histone deacetylase inhibitors (HDACis) and disulfiram to HIV-infected individuals on antiretroviral therapy significantly increased cell-associated HIV RNA in CD4+ T cells and in some cases plasma HIV RNA, this did not reduce the… CONTINUE READING
    90 Citations

    Topics from this paper.

    Clinical Interventions in HIV Cure Research.
    • 11
    Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    • 119
    Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption
    • 25
    • PDF
    Targeting Immune Checkpoint Molecules to Eliminate Latent HIV
    • 14
    • PDF
    Challenges and strategies for the eradication of the HIV reservoir.
    • 44
    Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
    • 81
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 70 REFERENCES
    Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    • 851
    • Highly Influential
    • PDF
    HIV: Shock and kill
    • 404
    • PDF
    A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.
    • Adam M Spivak, A. Andrade, +12 authors S. Deeks
    • Medicine
    • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
    • 2014
    • 134
    • PDF
    Altering cell death pathways as an approach to cure HIV infection
    • 55
    • PDF
    Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    • 258
    • PDF
    Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.
    • 600
    • PDF
    Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.
    • 215
    • PDF